Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01336088 · ClinicalTrials.gov registry record · Phase 2
ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease
A Phase 2 study, sponsored by Addex Pharma S.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT01336088 is a Phase 2 study that has completed, run by Addex Pharma S.A.. The registered enrollment target is 83 participants.
The verdict
NCT01336088, a Phase 2 study, has completed, sponsored by Addex Pharma S.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the safety and tolerability of ADX48621 in Parkinson's disease patients following four weeks of dosing. The secondary objectives of the study include the evaluation of the efficacy of ADX48621 compared with placebo in reducing levodopa induced dyskinesia in patients with Parkinson's; the evaluation of the effect of ADX48621 on symptoms of Parkinson's disease and patient ability to function, and the evaluation of the effect of coadministration of ADX48621 on L-dopa efficacy.
Interventions
- DRUG Placebo
- DRUG ADX48621
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01336088
The ClinicalTrials.gov registry entry for NCT01336088 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Addex Pharma S.A., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01336088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01336088 about?
NCT01336088 is a clinical study titled "ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease". The primary objective of the study is to evaluate the safety and tolerability of ADX48621 in Parkinson's disease patients following four weeks of dosing. The secondary objectives of the study include the evaluation of the efficacy of ADX48621 compared with placebo in reducing levodopa induced dyski...
What is the current status of trial NCT01336088?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2011-04. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01336088?
The interventions under investigation include: Placebo (DRUG), ADX48621 (DRUG).
Who is sponsoring clinical trial NCT01336088?
This trial is sponsored by Addex Pharma S.A., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.